Treatment Horizons

The Power of Two Dual regimens show promise in clinical trials by Chael Needle At the International AIDS Conference in Amsterdam last July, ViiV Healthcare shared its...

A new study reveals that patients who use PrEP (Pre-exposure Prophylaxis ), a combination of the antiretroviral medications emtricitabine and tenofovir called Truvada, to...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced on July 18, 2018 that the U.S. FDA has approved the use of SYMTUZA, the...

In February 2018, ViiV Healthcare announced the start of a forty-eight-week phase III study designed to determine whether adults with HIV-1 who have achieved...

Countdown Researcher Jia Xie discusses a cutting-edge treatment in development by Dann Dulin Block HIV by using the body’s own immune cells? Is it truly possible?! Well, such...

On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...

At the 16th European AIDS Conference in Milan, Italy, on October 25, 2017, Janssen Pharmaceutica, NV announced the results of its Phase 3 AMBER...

A newly completed study of 358 serodiscordant gay couples has not found a single case of HIV transmission in 16,889 acts of condomless anal...

On July 26, 2017, the Centers for Disease Control and Prevention released new data on the nation’s progress in HIV testing and treatment, showing...

Shock Value Research on SMYD2 shows potential to wake up the HIV reservoir by Chael Needle HIV latency—where HIV hides out in reservoirs, dormant and beyond the...